• 1
    TOMBOLA (Trial of Management of Borderline and Other Low grade Abnormal smears) Group. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. BJOG 2009;116:150614.
  • 2
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:48998.
  • 3
    NHSCSP 20. Colposcopy and Programme Management: Guidelines for the NHS Cervical Screening Programme, 2nd edn. Sheffield: NHSCSP, 2010. ISBN 978 1 84463 069 1.
  • 4
    Luesley D, Downey G. Value of normal colposcopy after an abnormal cervical smear report. J Low Genit Tract Dis 2009;13:337.
  • 5
    Smith MC, Keech SE, Perryman K, Soutter WP. A long-term study of women with normal colposcopy after referral with low grade cytological abnormalities. BJOG 2006;113:13218.
  • 6
    Teale GR, Moffitt DD, Mann CH, Luesley DM. Management guidelines for women with normal colposcopy after low grade cervical abnormalities: population study. BMJ 2000;320:16936.
  • 7
    Kourounis G, Ravazoula P, Michail G. Normal colposcopy following abnormal Pap smear evoking LGSIL: a follow-up study. Eur J Gynaecol Oncol 2004;25:6234.
  • 8
    Bjerre P, Silfverdal L, Dillner L, Hagmar B, Edvardsson H, Dillner J, et al. A randomized trial of basing treatment on human papillomavirus and/or cytology results in low grade cervical lesion triage. Am J Obstet Gynecol 2008; 199:24.e17.
  • 9
    Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006;195:34953.
  • 10
    Cotton SC, Sharp L, Little J, Duncan I, Alexander L, Cruickshank ME, et al. Trial of management of borderline and other low grade abnormal smears (TOMBOLA): trial design. Contemp Clin Trials 2006;27:44971.
  • 11
    Jacobs MV, Snijders PJ, van den Brule AJ. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:7915.
  • 12
    Kelly RS, Walker P, Kitchener H, Moss SM. Incidence of CIN grade 2 or worse in colposcopy-negative women with low grade cytological abnormalities. BJOG 2011;1471:204.
  • 13
    Cotton SC, Sharp L, Cochran C, Gray N, Cruickshank M, Smart L, et al. After-effects reported by women having follow-up cervical cytology tests in primary care: a cohort study within the TOMBOLA trial. Br J Gen Pract 2011;61:3912.
  • 14
    Cox JT, Schiffman M, Solomon D. Prospective follow-up suggest similar risk of subsequent cervical intra-epithelial Neoplasia grade 2 or 3 among women with cervical intra-epithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188:140611.
  • 15
    Guido R, Schiffman M, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance; a two year prospective study. Am J Obstet Gynecol 2003;188:14015.
  • 16
    Giannopoulos T, Butler-Manuel S, Tailor A, Demetriou E, Daborn L. Prevalence of high grade CIN following mild dyskaryotic smears in different age groups. Cytopathology 2005;16:27780.
  • 17
    Meijer CJLM, Berhof J, Castle P, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:51620.
  • 18
    Shafi MI, Dunn JA, Chenoy R, Buxton EJ, Williams C, Luesley DM. Digital imaging colposcopy, image analysis and quantification of the colposcopic image. Br J Obstet Gynaecol 1994;101:2348.
  • 19
    TOMBOLA (Trial of Management of Borderline and Other Low grade Abnormal smears) Group. Biopsy and selective recall is as effective as immediate LLETZ in the management of women with low grade smears referred for colposcopy. BMJ 2009;339:2548.
  • 20
    Carcopino X, Henry M, Mancini J, Giusiano S, Boubli L, Olive D, et al. Two years outcome of women infected with high risk HPV having normal colposcopy following low grade or equivocal cytological abnormalities: are HPV16 and 18 viral load clinically useful predictive markers? J Med Virol 2012;84:96472.
  • 21
    Matsumoto KH, Yasuo H, Reiko F, Naoyoshi T, Akinori O, Toshiharu Y, et al. Subsequent risks for cervical precancer and cancer in women with low grade squamous intraepithelial lesions unconfirmed by colposcopy-directed biopsy: results from a multicenter, prospective, cohort study. Int J Clin Oncol 2012;17:2339.
  • 22
    Shahmar M, Finn C, Peile E, Redman C, Cruickshank ME. A validity study of the national UK colposcopy objective structured clinical examination – is it a test fit for purpose? BJOG 2009;116:17969.
  • 23
    Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.
  • 24
    Wentzensen N, Walker J, Schiffman M, Yang HP, Zuna RE, Dunn ST, et al. Heterogeneity of high grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management. Int J Cancer 2013;132:14854.